新华制药2024年年报简析:增收不增利

证券之星
01 Apr

据证券之星公开数据整理,近期新华制药(000756)发布2024年年报。根据财报显示,新华制药增收不增利。截至本报告期末,公司营业总收入84.66亿元,同比上升4.51%,归母净利润4.7亿元,同比下降5.33%。按单季度数据看,第四季度营业总收入17.32亿元,同比上升8.04%,第四季度归母净利润1.26亿元,同比上升20.47%。本次财报公布的各项数据指标表现一般。其中,毛利率24.11%,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10